Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,84
KB-0,34
PKN128,48128,540,39
Msft420,9420,97-2,77
Nokia8,9328,9424,95
IBM230,4230,46-8,52
Mercedes-Benz Group AG50,7350,740,46
PFE26,5226,53-1,04
23.04.2026 16:53:58
Indexy online
AD Index online
select
AD Index online
 

  • 23.04.2026 16:53:11
PACIFIC (PACB.O, NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (USD)
1,59 -7,31 -0,13 2 742 263
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace:
Popis společnosti

Business Summary: Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops, and manufactures sequencing solutions. Its products and technology include HiFi long-read sequencing technology, which addresses a set of applications including human germline sequencing, plant and animal sciences, infectious disease, microbiology, oncology, and other applications. Its sequencing technology supports oncology research by enabling analysis of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), providing researchers with insight into cancer biology. It focuses on creating sequencing systems to provide customers with a view of genomes, transcriptomes, and epigenomes. Its customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Pacific Biosciences of California Inc revenues increased 4% to $160M. Net loss increased 76% to $546.4M. Revenues reflect Consumable revenue segment increase of 16% to $81.9M, Service And Other segment increase of 36% to $24.2M, Europe (including the Middle East and Africa) segment increase of 27% to $44.1M, Asia Pacific segment increase of 6% to $43.2M.



  • Poslední aktualizace:
Management společnosti
Data nejsou k dispozici